Form 4: Aprea Therapeutics Director Seizinger Acquires Shares and Warrants

Director Bernd R. Seizinger acquired common stock and warrants of Aprea Therapeutics, Inc. on March 13, 2024.

Summary

• On March 13, 2024, Bernd R. Seizinger, a director of Aprea Therapeutics, Inc., purchased 6,860 shares of common stock at a price of $7.29 per share.
• The director also acquired Tranche A and Tranche B warrants.
• The Tranche A warrants allow the purchase of 3,430 shares at an exercise price of $7.29 per share and expire on March 13, 2027, with potential early termination based on Phase 2 dose announcement for ATRN-119 and a VWAP of the common stock exceeding $14.58 for 30 consecutive trading days.
• The Tranche B warrants allow the purchase of 3,430 shares at an exercise price of $9.1125 per share and expire on March 13, 2029, with potential early termination based on Phase 2 dose announcement for APR-1051 and a VWAP of the common stock exceeding $18.225 for 30 consecutive trading days.
• Following the transaction, Seizinger directly owns 33,685 shares of common stock, 3,430 Tranche A warrants, and 3,430 Tranche B warrants.

Sentiment

Score: 6

Explanation: The director's purchase is a mildly positive signal, suggesting confidence. However, it's a single transaction and doesn't provide a comprehensive view of the company's overall health.

Positives

• A director's purchase of company stock and warrants can be seen as a positive signal, indicating confidence in the company's future prospects.

Risks

• The warrants have specific conditions for early termination based on clinical trial progress and stock price performance, which introduces uncertainty.

Future Outlook

The warrants' early termination clauses are tied to the announcement of Phase 2 dose recommendations for ATRN-119 and APR-1051, as well as the stock's VWAP reaching certain thresholds, suggesting these are key milestones for the company.

Industry Context

This filing reflects insider activity in a biotechnology company, which is common as executives and directors often have compensation packages that include stock and options. Monitoring these transactions can provide insights into management's sentiment about the company's prospects.

Comparison to Industry Standards

• Insider transactions are a common occurrence in publicly traded companies, particularly in the biotech sector where stock options and warrants are frequently used as part of compensation packages.
• Comparing the size and frequency of insider transactions at Aprea Therapeutics to those of its peers (e.g., companies like Mirati Therapeutics, Relay Therapeutics, or Black Diamond Therapeutics) could provide a benchmark for assessing the significance of this particular transaction.
• The terms of the warrants, such as the exercise price and expiration date, are also typical for the industry, but the early termination clauses tied to specific clinical milestones are worth noting as they align the warrant holders' interests with the company's clinical development progress.

Stakeholder Impact

• The director's purchase could positively influence shareholder sentiment.
• The warrant terms incentivize the company to achieve clinical milestones, potentially benefiting patients and other stakeholders.

Next Steps

• Monitor the progress of ATRN-119 and APR-1051 clinical trials, as the announcement of Phase 2 dose recommendations could trigger early warrant termination.
• Track the company's stock price to see if it reaches the VWAP thresholds required for early warrant termination.

Key Dates